Botanical and Plant-Derived Drugs Market 2022-2026: Scope
The botanical and plant-derived drugs market report covers the following areas:
Botanical and Plant-Derived Drugs Market 2022-2026: Drivers and Challenges
The increase in government initiatives is driving the botanical and plant-derived drugs market growth. Herbal medicines are getting significant attention from global healthcare systems. Governments across various countries have made substantial research investments in herbal medicines. Such initiatives will drive market growth during the forecast period.
The low acceptance among physicians is challenging the botanical and plant-derived drugs market growth. For instance, many physicians warn diabetic patients against taking herbal medicines, as there is no proper regulatory mechanism. Such issues may hamper the growth prospects of the market during the forecast period.
Botanical and Plant-Derived Drugs Market 2022-2026: Segmentation
By product, the market has been segmented into plant derived drugs and botanical drugs. The plant-derived drugs segment will have the highest market share growth during the forecast period. The increasing need for effective drugs for the treatment of chronic disorders such as cancer and diabetes has fueled the demand for plant-derived drugs.
By geography, the market has been segmented into Asia, Europe, North America, and Rest Of World (ROW). Asia will have the highest market share growth during the forecast period.
Learn more about the contribution of each segment of the market. Download a Free Sample
Botanical and Plant-Derived Drugs Market 2022-2026: Vendor Analysis
We provide a detailed analysis of around 25 vendors operating in the Botanical and Plant-Derived Drugs Market, including Bayer AG, Boehringer Ingelheim International GmbH, Dr. Willmar Schwabe GmbH, and Co. KG, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Johnson and Johnson Inc., Merck KGaA, Mitsubishi Chemical Corp., Novartis AG, Pierre Fabre SA, Protalix Biotherapeutics Inc., Quintis (Australia) Pty Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Tilray Inc., and Verdure Sciences Inc. among others.
Subscribe to our "Lite Plan" billed annually at USD 3000 that enables you to download 3 reports/year and view 3 reports/month.
Botanical and Plant-Derived Drugs Market 2022-2026: Key Highlights
- CAGR of the market during the forecast period 2022-2026
- Detailed information on factors that will assist botanical and plant-derived drugs market growth during the next five years
- Estimation of the botanical and plant-derived drugs market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the botanical and plant-derived drugs market
- Analysis of the market's competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of botanical and plant-derived drugs market vendors
Related Reports:
New Drug Delivery Systems Market by Route of Administration and Geography - Forecast and Analysis 2022-2026
Non-small Cell Lung Cancer Drugs Market by Product and Geography - Forecast and Analysis 2022-2026
Botanical And Plant-Derived Drugs Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.25% |
Market growth 2022-2026 |
USD 15.89 billion |
Market structure |
Fragmented |
YoY growth (%) |
7.02 |
Regional analysis |
Asia, Europe, North America, and Rest of World (ROW) |
Performing market contribution |
Asia at 45% |
Key consumer countries |
US, UK, Germany, Japan, and China |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
Bayer AG, Boehringer Ingelheim International GmbH, Dr. Willmar Schwabe GmbH and Co. KG, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Johnson and Johnson Inc., Merck KGaA, Mitsubishi Chemical Corp., Novartis AG, Pierre Fabre SA, Protalix Biotherapeutics Inc., Quintis (Australia) Pty Ltd., Sanofi SA, Sun Pharmaceutical Industries Ltd., Tilray Inc., and Verdure Sciences Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period, |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table Of Contents :
Executive Summary
Market Landscape
Market Sizing
- Market definition
- Market segment analysis
- Market size 2021
- Market outlook: Forecast for 2021-2026
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Product
- Market segments
- Comparison by Product
- Plant derived drugs - Market size and forecast 2021-2026
- Botanical drugs - Market size and forecast 2021-2026
- Market opportunity by Product
Customer Landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- Asia - Market size and forecast 2021-2026
- Europe - Market size and forecast 2021-2026
- North America - Market size and forecast 2021-2026
- Rest of World (ROW) - Market size and forecast 2021-2026
- US - Market size and forecast 2021-2026
- Japan - Market size and forecast 2021-2026
- China - Market size and forecast 2021-2026
- UK - Market size and forecast 2021-2026
- Germany - Market size and forecast 2021-2026
- Market opportunity by geography
Drivers, Challenges, and Trends
- Market drivers
- Market challenges
- Impact of drivers and challenges
- Market trends
Vendor Landscape
- Overview
- Vendor landscape
- Landscape disruption
- Industry risks
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Bayer AG
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline Plc
- Jazz Pharmaceuticals Plc
- Johnson and Johnson Inc.
- Merck KGaA
- Mitsubishi Chemical Corp.
- Novartis AG
- Pierre Fabre SA
- Sanofi SA
Appendix
- Scope of the report
- Inclusions and exclusions checklist
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article